The emergence of Retatrutide ZPHC, at a concentration of 120mg, is creating considerable excitement within the medical community. This innovative dual GIP and GLP-1 target medication appears to offer notable improvements in body shedding compared to existing therapies. Initial patient studies have shown substantial decreases in body fat percentage,